Drug Profile
Interleukin-3 biosimilar - Cangene
Alternative Names: Allevorin; SDZ 215134Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Class Antineoplastics; Interleukins
- Mechanism of Action Immunostimulants; Interleukin 3 stimulants; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Haematological disorders; Haematological malignancies; Preleukaemia
Most Recent Events
- 08 Oct 2002 Discontinued - Clinical-Phase-Unknown for Haematological malignancies in Germany (SC)
- 08 Oct 2002 Discontinued - Phase-III for Cancer in USA (IV)
- 08 Oct 2002 Discontinued - Phase-III for Haematological disorders in USA (Parenteral)